Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
1. Lexicon presents new pilavapadin data at the International Congress on Neuropathic Pain. 2. Findings show significant reduction of neuropathic pain in preclinical models. 3. Pilavapadin targets AAK1, promising for diverse neuropathic pain indications. 4. Fast Track designation from FDA enhances pilavapadin's development prospects. 5. Data supports Lexicon's innovative approach in pain management treatments.